MDR技術文書(附属書IIおよびIII)の構成方法 – 実践的コンプライアンスガイド

REPHINE SPEECH MARKS OPEN MEDICALDEVICES

Is your organisation fully prepared to structure MDR Technical Documentation under Annex II and Annex III?
REPHINE SPEECH MARKS CLOSE MEDICALDEVICES

About this Whitepaper

This guide translates the legal language of Annex II and Annex III into a practical, reviewer friendly structure that supports faster assessment by Notified Bodies. It explains how to present device information, design and manufacturing evidence, GSPR demonstrations, verification and validation data, clinical evaluation and PMS outputs in a coherent and logically connected way.
 
The document emphasises the MDR requirement for Technical Documentation to be clear, organised, readily searchable and unambiguous. It also highlights the most frequent causes of review delays including incomplete submissions, inconsistent terminology and dossiers that require reviewers to search for links between claims and evidence.
Through best practice recommendations and explanations of common Notified Body observations, the white paper guides manufacturers to create documentation that supports lifecycle consistency and reduces question cycles.

What’s changing?

Organisations must adapt to MDR review patterns in which Notified Bodies do not read dossiers linearly. Instead, they move quickly between intended purpose, classification, GSPR mapping, risk management, verification and validation, clinical evidence and PMS. To meet expectations, manufacturers need Technical Documentation that demonstrates:

  • Clean device definition including intended purpose, variants, accessories and Basic UDI DI scope
  • Complete and cohesive information supplied with the device including labels, IFU and promotional materials
  • Clear design and manufacturing information with traceable links between design inputs, outputs, risk controls and verification evidence
  • Robust GSPR mapping with precise evidence references and justification for applicability or non applicability
  • Risk management aligned with ISO 14971 and integrated with verification, validation, clinical evaluation, usability and PMS
  • Verification and validation evidence that is complete, traceable and supported by accredited laboratories
  • PMS systems that operate as lifecycle feedback mechanisms and drive updates to risk, clinical evidence and documentation
  • SSCP requirements for implantable and class III devices where transparency and alignment with clinical and PMS outputs are essential
These elements reflect Notified Body expectations for documentation that is consistent, traceable and supported by justifiable regulatory reasoning.

Why it matters for your business

Well structured MDR Technical Documentation directly influences review timelines, inspection performance and market access. Poor organisation or inconsistent evidence presentation typically leads to additional reviewer rounds and delayed CE marking.
 
Manufacturers must therefore:
  • Map all device information and evidence to a coherent MDR aligned structure
  • Maintain terminology consistency across all documents including CER, RMF, IFU and PMS
  • Demonstrate clear requirement to evidence traceability with updated GSPR matrices and verification and validation summaries
  • Strengthen design and risk management integration through complete traceability between user needs, design inputs, hazards, risk controls and testing
  • Ensure PMS outputs genuinely inform lifecycle safety and performance decisions and align with clinical and risk files
A mature dossier signals system control, regulatory readiness and a high degree of organisational quality. It supports operational efficiency and positions the business for smoother regulatory pathways.

Take action now

With the MDR in full effect and Notified Bodies operating under heavy demand, documentation quality has never been more important. Organisations that invest early in structuring, updating and maintaining their Technical Documentation will minimise delays, reduce review friction and build a more resilient compliance framework.
 
This white paper provides practical recommendations, traceability models, architecture templates and insights into common review pitfalls, helping manufacturers create a sustainable documentation system that remains compliant throughout the device lifecycle.
 

👉 Download the full white paper below to discover how to structure MDR Technical Documentation in a clear, reliable and reviewer ready way.

Download the White Paper below

 

MockUp Resource Hub Web

View our other resources and company news

ファーマコビジランスにおけるコンプライアンスとデータインテグリティの確保 QMS

製薬会社におけるグローバルなQMS(品質マネジメントシステム)の調和を推進

本ケーススタディでは、Rephineがグローバル製 ...
Read More
CSV CSV

規制下ライフサイエンスにおけるIT品質保証:重要なポイント

IT品質保証は、規制対象となるライフサイエンスにお ...
Read More
ファーマコビジランスにおけるコンプライアンスとデータインテグリティの確保 GxPコンサルティング

英国の医薬品品質システムにおける実用的なコンプライアンスと査察対応準備

英国の医薬品およびバイオテクノロジー企業が、MHR ...
Read More
バナー:EU MDR/IVDRにおける市販後監視(PMS)実務ガイド CSV

EMAによるEU GMP改訂ドラフトの実務ガイド

EUの新しい製造物責任指令(2024/2853)は ...
Read More
バナー:EU MDR/IVDRにおける市販後監視(PMS)実務ガイド ガイド

EU MDR/IVDRにおける市販後監視(PMS)実務ガイド

EUの新しい製造物責任指令(2024/2853)は ...
Read More
GMP基準の引き上げ ブログシリーズ ヘッダー画像 5月25日 GxPコンサルティング

医薬品SOPのためのAI:品質管理とコンプライアンスの変革

Rephineは、医薬品およびバイオテクノロジー企 ...
Read More

CAPAおよび逸脱管理の強化

RephineのカスタマイズされたGxPトレーニン ...
Read More
GMP基準の引き上げ ブログシリーズ ヘッダー画像 5月25日 GMP監査

EU GMP Annex 1とFDA無菌操作ガイド:コンプライアンスの橋渡し

EUと米国の規制当局は、同じ無菌性保証の目標を共有 ...
Read More
GMP基準の引き上げ ブログシリーズ ヘッダー画像 5月25日 GMP監査

GMPとGDP:医薬品の保管と輸送における品質保証

保管と輸送は単なるロジスティクスではなく、重要なG ...
Read More
お問い合わせ

お客様の保証の道のりを強化します

GMP第22章 ハイブリッドドキュメンテーション基準への適応